MarketCap
Facebook
X
Telegram
Organovo Holdings Revenue | ONVO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Organovo Holdings
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131 K | 144 K | 109 K | 370 K | 1.5 M | - | 2.2 M | 3.09 M | 4.6 M | 4.23 M | 1.48 M | 571 K | 379 K | 220 K | 1.2 M | - | 603 K | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.6 M | 109 K | 1.39 M |
Quarterly Revenue Organovo Holdings
| 2027-Q1 | 2026-Q4 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 K | - | 26 K | 28 K | 37 K | - | 24 K | 30 K | 39 K | - | 5 K | - | 75 K | - | 131 K | 77 K | 77 K | 1.5 M | - | - | - | - | - | - | - | - | 298 K | 298 K | 1.23 M | 668 K | 779 K | 779 K | 943 K | 1.1 M | 832 K | 946 K | 944 K | 812 K | 699 K | 2.4 M | 1.7 M | 891 K | 293 K | 689 K | 396 K | 306 K | 139 K | 139 K | - | 99 K | 135 K | 264 K | 129 K | - | 349 K | 1.08 M | 728 K | - | - | 232 K | 1.68 K | 1.68 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.4 M | 1.68 K | 497 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Biomerica
BMRA
|
4.45 M | $ 1.73 | 2.98 % | $ 5.04 M | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 5.93 | 1.87 % | $ 549 M | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 2.27 | 7.58 % | $ 681 M | USA |
 |
Neuronetics
STIM
|
149 M | $ 2.24 | 5.92 % | $ 148 M | USA |
 |
Agilent Technologies
A
|
6.95 B | $ 175.71 | 1.56 % | $ 49.9 B | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 354.37 | 2.67 % | $ 17.6 B | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
126 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
5.39 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
540 M | $ 11.95 | 1.1 % | $ 126 M |  China |
 |
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Bioventus
BVS
|
568 M | $ 14.71 | -1.67 % | $ 980 M | USA |
 |
Psychemedics Corporation
PMD
|
19.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 26.77 | -0.48 % | $ 25.4 B |  Niderland |
 |
Meridian Bioscience
VIVO
|
333 M | - | - | $ 1.49 B | USA |
 |
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
T2 Biosystems
TTOO
|
7.19 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
622 K | $ 0.56 | 3.12 % | $ 745 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 241.85 | 0.02 % | $ 26.8 B | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 232.05 | 0.7 % | $ 165 B | USA |
 |
DexCom
DXCM
|
4.66 B | $ 77.69 | -0.33 % | $ 30.3 B | USA |
 |
Castle Biosciences
CSTL
|
344 M | $ 33.16 | 0.24 % | $ 961 M | USA |
 |
Fulgent Genetics
FLGT
|
323 M | $ 20.41 | 1.54 % | $ 628 M | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
982 M | $ 174.47 | 3.19 % | $ 21.9 B | USA |
 |
Quotient Limited
QTNT
|
38.5 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 568.76 | 1.5 % | $ 45.7 B | USA |
 |
Illumina
ILMN
|
4.34 B | $ 271.02 | 0.59 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 275.32 | -1.44 % | $ 47.3 B | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 100.0 | 0.2 % | $ 6.75 B | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 68.8 | -0.6 % | $ 3.67 B | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 675.22 | 0.9 % | $ 19.5 B | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 667.03 | -0.07 % | $ 34.4 B | Schweiz |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.86 | 1.25 % | $ 3.82 M | USA |
 |
Neogen Corporation
NEOG
|
870 M | $ 12.31 | 0.98 % | $ 2.68 B | USA |
 |
National Research Corporation
NRC
|
137 M | $ 22.33 | 1.82 % | $ 500 M | USA |
 |
Natera
NTRA
|
2.31 B | $ 403.93 | 0.27 % | $ 55.2 B | USA |
 |
OPKO Health
OPK
|
148 M | $ 1.66 | 1.53 % | $ 1.25 B | USA |
 |
Precipio
PRPO
|
24 M | $ 19.23 | -3.9 % | $ 30.9 M | USA |
 |
RadNet
RDNT
|
2.04 B | $ 70.49 | 0.21 % | $ 5.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
8.25 B | $ 184.42 | -0.46 % | $ 14.5 B |  Irlanda |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 7.6 | 1.2 % | $ 317 M | USA |